Human cytomegalovirus tropism for mucosal myeloid dendritic cells

Reviews in Medical Virology

Volumn 24, Issue 6, 2014, Pages 379-395

  Hertel, Laura ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL POPULATION; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMORAL IMMUNITY; LANGERHANS CELL; MONOCYTE; MOUTH MUCOSA; MUCOSA CELL; MYELOID DENDRITIC CELL; NONHUMAN; REVIEW; VIRAL TROPISM; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS REACTIVATION; VIRUS TRANSMISSION; ANIMAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; GENETICS; IMMUNOLOGY; MUCOSA; PHYSIOLOGY; VIROLOGY;

ANIMALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DENDRITIC CELLS; HUMANS; MUCOUS MEMBRANE; VIRAL TROPISM;

EID: 84926144838     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1797     Document Type: Review

References (150)

1. Mocarski ES, Shenk T, Pass RF. Cytomegaloviruses. In Fields Virology, Knipe DM, Howley PM, (ed). Lippincott Williams & Wilkins: Philadelphia, 2007; 2701-2772.
2. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Current Topics in Microbiology and Immunology 2008; 325: 417-470.
3. Britt W. HCMV entry into host, establishment of infection, spread in host, mechanisms of tissue damage. In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, Arvin A, Campadelli-Fiume G, Mocarski E, et al., (eds). Cambridge University Press: Cambridge, 2007.
4. Pass RF. Cytomegalovirus. In Fields Virology, Howley DKP, (ed). Lippincott/The Williams & Wilkins Co.: Philadelphia, 2001; 2675-2705.
5. de Franca TR, de Albuquerque Tavares Carvalho A, Gomes VB, Gueiros LA, Porter SR, Leao JC. Salivary shedding of Epstein-Barr virus and cytomegalovirus in people infected or not by human immunodeficiency virus 1. Clinical Oral Investigations 2012; 16: 659-664. DOI: 10.1007/s00784-011-0548-5.
6. Griffin E, Krantz E, Selke S, Huang ML, Wald A. Oral mucosal reactivation rates of herpesviruses among HIV-1 seropositive persons. Journal of Medical Virology 2008; 80: 1153-1159. DOI: 10.1002/jmv.21214.
7. Miller CS, Berger JR, Mootoor Y, Avdiushko SA, Zhu H, Kryscio RJ. High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. Journal of Clinical Microbiology 2006; 44: 2409-2415. DOI: 44/7/2409 [pii], 10.1128/JCM.00256-06.
8. Cappuyns I, Gugerli P, Mombelli A. Viruses in periodontal disease-a review. Oral Diseases 2005; 11: 219-229. DOI: ODI1123 [pii], 910.1111/j.1601-0825.2005.01123.x
9. Correia-Silva Jde F, Victoria JM, Guimaraes AL, et al. Cytomegalovirus shedding in the oral cavity of allogeneic haematopoietic stem cell transplant patients. Oral Diseases 2007; 13: 163-169. DOI: ODI1240 [pii], 10.1111/j.1601-0825.2006.01240.x.
10. Chan BW, Woo JK, Liew CT. Cytomegalovirus infection of the nasopharynx. Journal of Clinical Pathology 2002; 55: 970-972.
11. Wejse C, Birkebaek NH, Nielsen LP, Andersen HM. Respiratory tract infections in cytomegalovirus-excreting and nonexcreting infants. Pediatric Infectious Disease Journal 2001; 20: 256-259.
12. Jutte A, Fatkenheuer G, Hell K, Salzberger B. CMV sinusitis as the initial manifestation of AIDS. HIV Medicine 2000; 1: 123-124. DOI: hiv015 [pii].
13. Marks SC, Upadhyay S, Crane L. Cytomegalovirus sinusitis. A new manifestation of AIDS. Archives of Otolaryngology - Head and Neck Surgery 1996; 122: 789-791.
14. Steinman RM. Dendritic cells: understanding immunogenicity. European Journal of Immunology 2007; 37(Suppl 1): S53-60. DOI: 10.1002/eji.200737400.
15. Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. Journal of Experimental Medicine 2000; 192: 219-226.
16. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st century: a tool for decisionmaking, Committee to Study Priorities for Vaccine Development, Division of Health Promotion and Disease Prevention, Institute of Medicine, Washington, DC. 1999.
17. Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clinical Infectious Diseases 2004; 39: 233-239. DOI: 10.1086/421999, CID32962 [pii].
18. Griffiths P, Plotkin S, Mocarski E, et al. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 2013; 31(Suppl 2): B197-203. DOI: S0264-410X(12)01534-4 [pii], 10.1016/j.vaccine.2012.10.074.
19. Schleiss MR, Heineman TC. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Review of Vaccines 2005; 4: 381-406.
20. Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Review of Vaccines 2010; 9: 1303-1314. DOI: 10.1586/erv.10.125.
21. Schleiss MR. Cytomegalovirus vaccine development. Current Topics in Microbiology and Immunology 2008; 325: 361-382.
22. Heineman TC, Schleiss M, Bernstein DI, et al. A phase 1 study of 4 live, recombinant human cytomegalovirus towne/toledo chimeric vaccines. Journal of Infectious Diseases 2006; 193: 1350-1360. DOI: JID35356 [pii], 10.1086/503365.
23. Guy B. Strategies to improve the effect of vaccination in the elderly: the vaccine producer's perspective. Journal of Comparative Pathology 2010; 142(Suppl 1): S133-137. DOI: S0021-9975(09)00324-7 [pii], 10.1016/j.jcpa.2009.09.009.
24. Belyakov IM, Ahlers JD. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? Journal of Immunology 2009; 183: 6883-6892. DOI: 183/11/6883 [pii], 10.4049/jimmunol.0901466.
25. Cattamanchi A, Posavad CM, Wald A, et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clinical and Vaccine Immunology 2008; 15: 1638-1643. DOI: CVI.00167-08 [pii], 10.1128/CVI.00167-08.
26. Holmgren J, Svennerholm AM. Vaccines against mucosal infections. Current Opinion in Immunology 2012; 24: 343-353. DOI: S0952-7915(12)00063-5 [pii], 10.1016/j.coi.2012.03.014.
27. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nature Reviews Immunology 2012; 12: 592-605. DOI: nri3251 [pii], 10.1038/nri3251.
28. Skenderi F, Jonjic S. Viral vaccines and vectors-some lessons from cytomegaloviruses. Periodicum Biologorum 2012; 114: 201-210.
29. McVoy MA. Cytomegalovirus vaccines. Clinical Infectious Diseases 2013; 57(Suppl 4): S196-199. DOI: cit587 [pii], 10.1093/cid/cit587.
30. Feuchtinger T, Opherk K, Bicanic O, et al. Dendritic cell vaccination in an allogeneic stem cell recipient receiving a transplant from a human cytomegalovirus (HCMV)-seronegative donor: induction of a HCMV-specific T (helper) cell response. Cytotherapy 2010; 12: 945-950. DOI: 10.3109/14653241003587645.
31. Kapp M, Tan SM, Einsele H, Grigoleit G. Adoptive immunotherapy of HCMV infection. Cytotherapy 2007; 9: 699-711. DOI: 782850371 [pii], 10.1080/14653240701656046.
32. Moharamzadeh K, Brook IM, Van Noort R, Scutt AM, Thornhill MH. Tissue-engineered oral mucosa: a review of the scientific literature. Journal of Dental Research 2007; 86: 115-124. DOI: 86/2/115 [pii].
33. Novak N, Haberstok J, Bieber T, Allam JP. The immune privilege of the oral mucosa. Trends in Molecular Medicine 2008; 14: 191-198. DOI: S1471-4914(08)00072-5 [pii], 10.1016/j.molmed.2008.03.001.
34. Allam JP, Novak N, Fuchs C, et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. Journal of Allergy and Clinical Immunology 2003; 112: 141-148. DOI: S0091674903015380 [pii]
35. Allam JP, Niederhagen B, Bucheler M, et al. Comparative analysis of nasal and oral mucosa dendritic cells. Allergy 2006; 61: 166-172. DOI: ALL965 [pii], 10.1111/j.1398-9995.2005.00965.x.
36. Allam JP, Peng WM, Appel T, et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. Journal of Allergy and Clinical Immunology 2008; 121: 368-374 e361. DOI: S0091-6749(07)01838-6 [pii], 10.1016/j.jaci.2007.09.045.
37. Allam JP, Stojanovski G, Friedrichs N, et al. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 2008; 63: 720-727. DOI: ALL1611 [pii], 10.1111/j.1398-9995.2007.01611.x.
38. Barrett AW, Cruchley AT, Williams DM. Oral mucosal Langerhans' cells. Critical Reviews in Oral Biology and Medicine 1996; 7: 36-58.
39. Cutler CW, Jotwani R. Dendritic cells at the oral mucosal interface. Journal of Dental Research 2006; 85: 678-689. DOI: 85/8/678 [pii].
40. Cruchley AT, Williams DM, Farthing PM, Lesch CA, Squier CA. Regional variation in Langerhans cell distribution and density in normal human oral mucosa determined using monoclonal antibodies against CD1, HLADR, HLADQ and HLADP. Journal of Oral Pathology and Medicine 1989; 18: 510-516.
41. Jaitley S, Saraswathi T. Pathophysiology of Langerhans cells. Journal of Oral and Maxillofacial Pathology 2012; 16: 239-244. DOI: 10.4103/0973-029X.99077, JOMFP-16-239 [pii].
42. Ito H, Takekoshi T, Miyauchi M, et al. Three-dimensional appearance of Langerhans cells in human gingival epithelium as revealed by confocal laser scanning microscopy. Archives of Oral Biology 1998; 43: 741-744. DOI: S0003996998000661 [pii].
43. Feng P, Yee KK, Rawson NE, Feldman LM, Feldman RS, Breslin PA. Immune cells of the human peripheral taste system: dominant dendritic cells and CD4 T cells. Brain, Behavior, and Immunity 2009; 23: 760-766. DOI: S0889-1591(09)00056-7 [pii], 10.1016/j.bbi.2009.02.016.
44. Jotwani R, Palucka AK, Al-Quotub M, et al. Mature dendritic cells infiltrate the T cell-rich region of oral mucosa in chronic periodontitis: in situ, in vivo, and in vitro studies. Journal of Immunology 2001; 167: 4693-4700.
45. Farthing PM, Matear P, Cruchley AT. The activation of Langerhans cells in oral lichen planus. Journal of Oral Pathology and Medicine 1990; 19: 81-85.
46. Jahnsen FL, Gran E, Haye R, Brandtzaeg P. Human nasal mucosa contains antigen-presenting cells of strikingly different functional phenotypes. American Journal of Respiratory Cell and Molecular Biology 2004; 30: 31-37. DOI: 10.1165/rcmb.2002-0230OC, 2002-0230OC [pii]
47. Mascarell L, Lombardi V, Louise A, et al. Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells. Journal of Allergy and Clinical Immunology 2008; 122: 603-609 e605. DOI: S0091-6749(08)01185-8 [pii], 10.1016/j.jaci.2008.06.034
48. Schon-Hegrad MA, Oliver J, McMenamin PG, Holt PG. Studies on the density, distribution, and surface phenotype of intraepithelial class II major histocompatibility complex antigen (Ia)-bearing dendritic cells (DC) in the conducting airways. Journal of Experimental Medicine 1991; 173: 1345-1356.
49. Debertin AS, Tschernig T, Tonjes H, Kleemann WJ, Troger HD, Pabst R. Nasal-associated lymphoid tissue (NALT): frequency and localization in young children. Clinical and Experimental Immunology 2003; 134: 503-507. DOI: 2311 [pii].
50. Sinzger C, Digel M, Jahn G. Cytomegalovirus cell tropism. Current Topics in Microbiology and Immunology 2008; 325: 63-83.
51. Hobom U, Brune W, Messerle M, Hahn G, Koszinowski UH. Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. Journal of Virology 2000; 74: 7720-7729.
52. Vanarsdall AL, Chase MC, Johnson DC. Human cytomegalovirus glycoprotein gO complexes with gH/gL, promoting interference with viral entry into human fibroblasts but not entry into epithelial cells. Journal of Virology 2011; 85: 11638-11645. DOI: JVI.05659-11 [pii], 10.1128/JVI.05659-11.
53. Isaacson MK, Compton T. Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. Journal of Virology 2009; 83: 3891-3903. DOI: JVI.01251-08 [pii], 10.1128/JVI.01251-08.
54. Hahn G, Revello MG, Patrone M, et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. Journal of Virology 2004; 78: 10023-10033.
55. Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 18153-18158.
56. Wang D, Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. Journal of Virology 2005; 79: 10330-10338.
57. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. Journal of Virology 2006; 80: 710-722.
58. Ryckman BJ, Rainish BL, Chase MC, et al. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. Journal of Virology 2008; 82: 60-70.
59. Sinzger C. Entry route of HCMV into endothelial cells. Journal of Clinical Virology 2008; 41: 174-179.
60. Patrone M, Secchi M, Bonaparte E, Milanesi G, Gallina A. Cytomegalovirus UL131-128 products promote gB conformational transition and gB-gH interaction during entry into endothelial cells. Journal of Virology 2007; 81: 11479-11488.
61. Akter P, Cunningham C, McSharry BP, et al. Two novel spliced genes in human cytomegalovirus. Journal of General Virology 2003; 84: 1117-1122.
62. Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, Koszinowski U. Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. Journal of General Virology 2006; 87: 2451-2460.
63. Ogawa-Goto K, Tanaka K, Gibson W, et al. Microtubule network facilitates nuclear targeting of human cytomegalovirus capsid. Journal of Virology 2003; 77: 8541-8547.
64. Hertel L, Lacaille VG, Strobl H, Mellins ED, Mocarski ES. Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus. Journal of Virology 2003; 77: 7563-7574.
65. Lauron EJ, Yu D, Fehr AR, Hertel L. Human cytomegalovirus infection of langerhans-type dendritic cells does not require the presence of the gH/gL/UL128-131A complex and is blocked after nuclear deposition of viral genomes in immature cells. Journal of Virology 2014; 88: 403-416. DOI: JVI.03062-13 [pii], 10.1128/JVI.03062-13.
66. Lee AW, Hertel L, Louie RK, et al. Human cytomegalovirus alters localization of MHC class II and dendrite morphology in mature Langerhans cells. Journal of Immunology 2006; 177: 3960-3971.
67. Lee AW, Wang N, Hornell TM, et al. Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels. Molecular Immunology 2011; 48: 1160-1167. DOI: S0161-5890(11)00070-8 [pii], 10.1016/j.molimm.2011.02.010.
68. Strunk D, Rappersberger K, Egger C, et al. Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood 1996; 87: 1292-1302.
69. Rozis G, Benlahrech A, Duraisingham S, Gotch F, Patterson S. Human Langerhans' cells and dermal-type dendritic cells generated from CD34 stem cells express different toll-like receptors and secrete different cytokines in response to toll-like receptor ligands. Immunology 2008; 124: 329-338. DOI: IMM2770 [pii], 10.1111/j.1365-2567.2007.02770.x.
70. Sambucetti LC, Cherrington JM, Wilkinson GW, Mocarski ES. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO Journal 1989; 8: 4251-4258.
71. Lang D, Fickenscher H, Stamminger T. Analysis of proteins binding to the proximal promoter region of the human cytomegalovirus IE-1/2 enhancer/promoter reveals both consensus and aberrant recognition sequences for transcription factors Sp1 and CREB. Nucleic Acids Research 1992; 20: 3287-3295.
72. Hunninghake GW, Monick MM, Liu B, Stinski MF. The promoter-regulatory region of the major immediate-early gene of human cytomegalovirus responds to T-lymphocyte stimulation and contains functional cyclic AMP-response elements. Journal of Virology 1989; 63: 3026-3033.
73. Kothari S, Baillie J, Sissons JG, Sinclair JH. The 21bp repeat element of the human cytomegalovirus major immediate early enhancer is a negative regulator of gene expression in undifferentiated cells. Nucleic Acids Research 1991; 19: 1767-1771.
74. Shelbourn SL, Kothari SK, Sissons JG, Sinclair JH. Repression of human cytomegalovirus gene expression associated with a novel immediate early regulatory region binding factor. Nucleic Acids Research 1989; 17: 9165-9171.
75. Zhang XY, Ni YS, Saifudeen Z, Asiedu CK, Supakar PC, Ehrlich M. Increasing binding of a transcription factor immediately downstream of the cap site of a cytomegalovirus gene represses expression. Nucleic Acids Research 1995; 23: 3026-3033. DOI: 5a0111 [pii].
76. Huang TH, Oka T, Asai T, et al. Repression by a differentiation-specific factor of the human cytomegalovirus enhancer. Nucleic Acids Research 1996; 24: 1695-1701.
77. Zweidler-Mckay PA, Grimes HL, Flubacher MM, Tsichlis PN. Gfi-1 encodes a nuclear zinc finger protein that binds DNA and functions as a transcriptional repressor. Molecular and Cellular Biology 1996; 16: 4024-4034.
78. Liu R, Baillie J, Sissons JG, Sinclair JH. The transcription factor YY1 binds to negative regulatory elements in the human cytomegalovirus major immediate early enhancer/promoter and mediates repression in non-permissive cells. Nucleic Acids Research 1994; 22: 2453-2459.
79. Bain M, Mendelson M, Sinclair J. Ets-2 repressor factor (ERF) mediates repression of the human cytomegalovirus major immediate-early promoter in undifferentiated non-permissive cells. Journal of General Virology 2003; 84: 41-49.
80. + cells. Journal of Virology 2010; 84: 5594-5604. DOI: JVI.00348-10 [pii], 10.1128/JVI.00348-10.
81. Negorev D, Maul GG. Cellular proteins localized at and interacting within ND10/PML nuclear bodies/PODs suggest functions of a nuclear depot. Oncogene 2001; 20: 7234-7242. DOI: 10.1038/sj.onc.1204764.
82. Bernardi R, Pandolfi PP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nature Reviews Molecular Cell Biology 2007; 8: 1006-1016. DOI: nrm2277 [pii], 10.1038/nrm2277.
83. Lallemand-Breitenbach V, de The H. PML nuclear bodies. Cold Spring Harbor Perspectives in Biology 2010; 2: a000661. DOI: cshperspect.a000661 [pii], 10.1101/cshperspect.a000661.
84. Woodhall DL, Groves IJ, Reeves MB, Wilkinson G, Sinclair JH. Human Daxx-mediated repression of human cytomegalovirus gene expression correlates with a repressive chromatin structure around the major immediate early promoter. Journal of Biological Chemistry 2006; 281: 37652-37660.
85. Lukashchuk V, McFarlane S, Everett RD, Preston CM. Human cytomegalovirus protein pp71 displaces the chromatin-associated factor ATRX from nuclear domain 10 at early stages of infection. Journal of Virology 2008; 82: 12543-12554. DOI: JVI.01215-08 [pii], 10.1128/JVI.01215-08.
86. Hwang J, Kalejta RF. Proteasome-dependent, ubiquitin-independent degradation of Daxx by the viral pp71 protein in human cytomegalovirus-infected cells. Virology 2007; 367: 334-338. DOI: S0042-6822(07)00402-3 [pii], 10.1016/j.virol.2007.05.037.
87. Saffert RT, Kalejta RF. Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression. Journal of Virology 2006; 80: 3863-3871. DOI: 80/8/3863 [pii], 10.1128/JVI.80.8.3863-3871.2006.
88. Tavalai N, Papior P, Rechter S, Stamminger T. Nuclear domain 10 components promyelocytic leukemia protein and hDaxx independently contribute to an intrinsic antiviral defense against human cytomegalovirus infection. Journal of Virology 2008; 82: 126-137. DOI: JVI.01685-07 [pii], 10.1128/JVI.01685-07.
89. Tavalai N, Stamminger T. Intrinsic cellular defense mechanisms targeting human cytomegalovirus. Virus Research 2011; 157: 128-133. DOI: S0168-1702(10)00361-8 [pii], 10.1016/j.virusres.2010.10.002.
90. Ahn JH, Hayward GS. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells. Journal of Virology 1997; 71: 4599-4613.
91. Korioth F, Maul GG, Plachter B, Stamminger T, Frey J. The nuclear domain 10 (ND10) is disrupted by the human cytomegalovirus gene product IE1. Experimental Cell Research 1996; 229: 155-158. DOI: S0014-4827(96)90353-5 [pii], 10.1006/excr.1996.0353.
92. Wilkinson GW, Kelly C, Sinclair JH, Rickards C. Disruption of PML-associated nuclear bodies mediated by the human cytomegalovirus major immediate early gene product. Journal of General Virology 1998; 79 (Pt 5): 1233-1245.
93. Nevels M, Paulus C, Shenk T. Human cytomegalovirus immediate-early 1 protein facilitates viral replication by antagonizing histone deacetylation. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 17234-17239. DOI: 0407933101 [pii], 10.1073/pnas.0407933101.
94. Park JJ, Kim YE, Pham HT, Kim ET, Chung YH, Ahn JH. Functional interaction of the human cytomegalovirus IE2 protein with histone deacetylase 2 in infected human fibroblasts. Journal of General Virology 2007; 88: 3214-3223. DOI: 88/12/3214 [pii], 10.1099/vir.0.83171-0.
95. Saffert RT, Kalejta RF. Human cytomegalovirus gene expression is silenced by Daxx-mediated intrinsic immune defense in model latent infections established in vitro. Journal of Virology 2007; 81: 9109-9120. DOI: JVI.00827-07 [pii], 10.1128/JVI.00827-07.
96. Reeves MB, Lehner PJ, Sissons JG, Sinclair JH. An in vitro model for the regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin remodelling. Journal of General Virology 2005; 86: 2949-2954.
97. Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 4140-4145.
98. + bone marrow progenitors. Journal of General Virology 1996; 77 (Pt 12): 3099-3102.
99. Bolovan-Fritts CA, Mocarski ES, Wiedeman JA. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 1999; 93: 394-398.
100. Khaiboullina SF, Maciejewski JP, Crapnell K, et al. Human cytomegalovirus persists in myeloid progenitors and is passed to the myeloid progeny in a latent form. British Journal of Haematology 2004; 126: 410-417. DOI: 10.1111/j.1365-2141.2004.05056.x, BJH5056 [pii].
101. Reeves MB, Sinclair JH. Analysis of latent viral gene expression in natural and experimental latency models of human cytomegalovirus and its correlation with histone modifications at a latent promoter. Journal of General Virology 2010; 91: 599-604. DOI: vir.0.015602-0 [pii], 10.1099/vir.0.015602-0.
102. Reeves M, Sinclair J. Aspects of human cytomegalovirus latency and reactivation. Current Topics in Microbiology and Immunology 2008; 325: 297-313.
103. Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. Journal of General Virology 2006; 87: 1763-1779. DOI: 87/7/1763 [pii], 10.1099/vir.0.81891-0.
104. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. Journal of Experimental Medicine 1994; 179: 1109-1118.
105. van der Aar AM, Sylva-Steenland RM, Bos JD, Kapsenberg ML, de Jong EC, Teunissen MB. Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. Journal of Immunology 2007; 178: 1986-1990. DOI: 178/4/1986 [pii].
106. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annual Review of Immunology 2000; 18: 767-811.
107. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001; 106: 259-262.
108. Riegler S, Hebart H, Einsele H, Brossart P, Jahn G, Sinzger C. Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. Journal of General Virology 2000; 81: 393-399.
109. Raftery MJ, Schwab M, Eibert SM, Samstag Y, Walczak H, Schonrich G. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity 2001; 15: 997-1009.
110. Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 2002; 99: 2913-2921.
111. Grigoleit U, Riegler S, Einsele H, et al. Human cytomegalovirus induces a direct inhibitory effect on antigen presentation by monocyte-derived immature dendritic cells. British Journal of Haematology 2002; 119: 189-198. DOI: 3798 [pii].
112. Beck K, Meyer-Konig U, Weidmann M, Nern C, Hufert FT. Human cytomegalovirus impairs dendritic cell function: a novel mechanism of human cytomegalovirus immune escape. European Journal of Immunology 2003; 33: 1528-1538.
113. Senechal B, Boruchov AM, Reagan JL, Hart DN, Young JW. Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood 2004; 103: 4207-4215.
114. + T cells. Journal of General Virology 2005; 86: 275-284.
115. Haspot F, Lavault A, Sinzger C, et al. Human cytomegalovirus entry into dendritic cells occurs via a macropinocytosis-like pathway in a pH-independent and cholesterol-dependent manner. PLoS One 2012; 7: e34795. DOI: 10.1371/journal.pone.0034795, PONE-D-11-14831 [pii].
116. Varani S, Frascaroli G, Homman-Loudiyi M, Feld S, Landini MP, Soderberg-Naucler C. Human cytomegalovirus inhibits the migration of immature dendritic cells by down-regulating cell-surface CCR1 and CCR5. Journal of Leukocyte Biology 2005; 77: 219-228. DOI: jlb.0504301 [pii], 10.1189/jlb.0504301.
117. Halary F, Amara A, Lortat-Jacob H, et al. Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Immunity 2002; 17: 653-664.
118. Plazolles N, Humbert JM, Vachot L, Verrier B, Hocke C, Halary F. Pivotal advance: The promotion of soluble DC-SIGN release by inflammatory signals and its enhancement of cytomegalovirus-mediated cis-infection of myeloid dendritic cells. Journal of Leukocyte Biology 2011; 89: 329-342. DOI: jlb.0710386 [pii], 10.1189/jlb.0710386.
119. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. Journal of Experimental Medicine 2003; 197: 823-829. DOI: 10.1084/jem.20021840, jem.20021840 [pii].
120. Relloso M, Puig-Kroger A, Pello OM, et al. DC-SIGN (CD209) expression is IL-4 dependent and is negatively regulated by IFN, TGF-beta, and anti-inflammatory agents. Journal of Immunology 2002; 168: 2634-2643.
121. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. Journal of General Virology 1991; 72(Pt 9): 2059-2064.
122. Reeves MB, Compton T. Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells. Journal of Virology 2011; 85: 12750-12758. DOI: JVI.05878-11 [pii], 10.1128/JVI.05878-11.
123. Reeves MB, Sinclair JH. Circulating dendritic cells isolated from healthy seropositive donors are sites of human cytomegalovirus reactivation in vivo. Journal of Virology 2013; 87: 10660-10667. DOI: JVI.01539-13 [pii], 10.1128/JVI.01539-13.
124. Varani S, Frascaroli G, Gibellini D, et al. Impaired dendritic cell immunophenotype and function in heart transplant patients undergoing active cytomegalovirus infection. Transplantation 2005; 79: 219-227.
125. de Jong MA, Geijtenbeek TB. Langerhans cells in innate defense against pathogens. Trends in Immunology 2010; 31: 452-459. DOI: S1471-4906(10)00118-3 [pii], 10.1016/j.it.2010.08.002.
126. Cunningham AL, Abendroth A, Jones C, Nasr N, Turville S. Viruses and Langerhans cells. Immunology and Cell Biology 2010; 88: 416-423. DOI: icb201042 [pii], 10.1038/icb.2010.42.
127. de Witte L, Nabatov A, Pion M, et al. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nature Medicine 2007; 13: 367-371. DOI: nm1541 [pii], 10.1038/nm1541.
128. Mc Dermott R, Ziylan U, Spehner D, et al. Birbeck granules are subdomains of endosomal recycling compartment in human epidermal Langerhans cells, which form where Langerin accumulates. Molecular Biology of the Cell 2002; 13: 317-335. DOI: 10.1091/mbc.01-06-0300.
129. Neumann AK, Thompson NL, Jacobson K. Distribution and lateral mobility of DC-SIGN on immature dendritic cells--implications for pathogen uptake. Journal of Cell Science 2008; 121: 634-643. DOI: jcs.022418 [pii], 10.1242/jcs.022418.
130. Soilleux EJ, Morris LS, Leslie G, et al. Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. Journal of Leukocyte Biology 2002; 71: 445-457.
131. Arrighi JF, Pion M, Garcia E, et al. DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. Journal of Experimental Medicine 2004; 200: 1279-1288. DOI: jem.20041356 [pii], 10.1084/jem.20041356.
132. Freer G, Matteucci D. Influence of dendritic cells on viral pathogenicity. PLoS Pathogens 2009; 5: e1000384. DOI: 10.1371/journal.ppat.1000384.
133. Cavrois M, Neidleman J, Greene WC. The achilles heel of the trojan horse model of HIV-1 trans-infection. PLoS Pathogens 2008; 4: e1000051. DOI: 10.1371/journal.ppat.1000051.
134. Geijtenbeek TB, van Kooyk Y. DC-SIGN: a novel HIV receptor on DCs that mediates HIV-1 transmission. Current Topics in Microbiology and Immunology 2003; 276: 31-54.
135. de Witte L, Nabatov A, Geijtenbeek TB. Distinct roles for DC-SIGN+-dendritic cells and Langerhans cells in HIV-1 transmission. Trends in Molecular Medicine 2008; 14: 12-19. DOI: S1471-4914(07)00218-3 [pii], 10.1016/j.molmed.2007.11.001.
136. Soilleux EJ, Coleman N. Langerhans cells and the cells of Langerhans cell histiocytosis do not express DC-SIGN. Blood 2001; 98: 1987-1988.
137. Powers C, DeFilippis V, Malouli D, Fruh K. Cytomegalovirus immune evasion. Current Topics in Microbiology and Immunology 2008; 325: 333-359.
138. Rolle A, Olweus J. Dendritic cells in cytomegalovirus infection: viral evasion and host countermeasures. Apmis 2009; 117: 413-426.
139. Gredmark-Russ S, Soderberg-Naucler C. Dendritic cell biology in human cytomegalovirus infection and the clinical consequences for host immunity and pathology. Virulence 2012; 3. DOI: 22239 [pii].
140. Moutaftsi M, Brennan P, Spector SA, Tabi Z. Impaired lymphoid chemokine-mediated migration due to a block on the chemokine receptor switch in human cytomegalovirus-infected dendritic cells. Journal of Virology 2004; 78: 3046-3054.
141. Kessler T, Reich M, Jahn G, et al. Human cytomegalovirus infection interferes with major histocompatibility complex type II maturation and endocytic proteases in dendritic cells at multiple levels. Journal of General Virology 2008; 89: 2427-2436. DOI: 89/10/2427 [pii], 10.1099/vir.0.2008/001610-0.
142. Frascaroli G, Varani S, Mastroianni A, et al. Dendritic cell function in cytomegalovirus-infected patients with mononucleosis. Journal of Leukocyte Biology 2006; 79: 932-940.
143. Wagner CS, Walther-Jallow L, Buentke E, Ljunggren HG, Achour A, Chambers BJ. Human cytomegalovirus-derived protein UL18 alters the phenotype and function of monocyte-derived dendritic cells. Journal of Leukocyte Biology 2008; 83: 56-63. DOI: jlb.0307181 [pii], 10.1189/jlb.0307181.
144. Chang WL, Baumgarth N, Yu D, Barry PA. Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. Journal of Virology 2004; 78: 8720-8731. DOI: 10.1128/JVI.78.16.8720-8731.2004, 78/16/8720 [pii].
145. Raftery MJ, Wieland D, Gronewald S, Kraus AA, Giese T, Schonrich G. Shaping phenotype, function, and survival of dendritic cells by cytomegalovirus-encoded IL-10. Journal of Immunology 2004; 173: 3383-3391. DOI: 173/5/3383 [pii].
146. Sinclair J Manipulation of dendritic cell functions by human cytomegalovirus. Expert Reviews in Molecular Medicine 2008; 10: e35.
147. Sivard P, Dezutter-Dambuyant C, Kanitakis J, et al. In vitro reconstructed mucosa-integrating Langerhans' cells. Experimental Dermatology 2003; 12: 346-355. DOI: 108 [pii].
148. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. Journal of Pharmaceutical Sciences 1992; 81: 1-10.
149. Sauer C, Klobuch S, Herr W, Thomas S, Plachter B. Subviral dense bodies of human cytomegalovirus stimulate maturation and activation of monocyte-derived immature dendritic cells. Journal of Virology 2013; 87: 11287-11291. DOI: JVI.01429-13 [pii], 10.1128/JVI.01429-13.
150. Cayatte C, Schneider-Ohrum K, Wang Z, et al. Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells. Journal of Virology 2013; 87: 11107-11120. DOI: JVI.01554-13 [pii], 10.1128/JVI.01554-13.